# Ziihera® (zanidatamab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zanidatamab

> The FDA approved Ziihera® (zanidatamab), sponsored by Jazz Pharmaceuticals plc (JAZZ), on August 25, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Ziihera® (zanidatamab) FDA approved?

Yes. The FDA approved Ziihera® (zanidatamab), sponsored by Jazz Pharmaceuticals plc (JAZZ), on August 25, 2026. Press release filed with the SEC (EX-99): "DUBLIN, August 25, 2026 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+)." [Calendar and source filings](https://sec-api.dev/pdufa/zanidatamab)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-058864, https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/zanidatamab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ziihera® (zanidatamab) |
| Codes | ZW25, JZP598 |
| Sponsor | Jazz Pharmaceuticals plc (JAZZ) https://sec-api.dev/companies/jazz/catalysts |
| Indications | [with previously treated, unresectable or metastatic her2-positive](https://sec-api.dev/indications/with-previously-treated-unresectable-or-metastatic-her2-positive), with 1l her2+ locally advanced or metastatic gea, with first-line, first-line her2+ locally advanced or metastatic gea, with previously treated, unresectable or metastatic her2+, [with previously-treated, unresectable or metastatic her2-positive](https://sec-api.dev/indications/with-previously-treated-unresectable-or-metastatic-her2-positive), Gastric Neoplasms, [Biliary Tract Cancer](https://sec-api.dev/indications/biliary-tract-cancer) |
| Modality | antibody |
| FDA designations | accelerated, breakthrough, fast track, orphan, priority review |

## Timeline

### November 20, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with previously treated, unresectable or metastatic HER2-positive.
- First seen 2024-11-21, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-262940): " Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR)." https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/d832756dex991.htm
- SEC Form 8-K (accession 0001193125-24-262940): "On November 20, 2024, Jazz Pharmaceuticals plc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") accelerated approval of Ziihera®(zanidatamab-hrii) 50mg/mL for injection for IV for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test." https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/d832756d8k.htm
- SEC Form 10-K (accession 0001232524-25-000011): "In November 2024, we announced FDA accelerated approval of Ziihera for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, triggering a regulatory milestone payment of $25.0 million, which was capitalized as an intangible asset on our consolidated balance sheet." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000011/jazz-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-262940): "Jazz Pharmaceuticals Announces U.S. FDA Approval of" https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/d832756dex991.htm
- SEC Form 8-K (accession 0001193125-24-263398): "As announced on November 21, 2024, the FDA granted accelerated approval of Ziihera® (zanidatamab-hrii, a bispecific HER2-directed antibody that binds to two extracellular sites on HER2) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive BTC, as detected by an FDA-approved test." https://www.sec.gov/Archives/edgar/data/1937653/000119312524263398/d769907d8k.htm
- SEC Form 8-K (accession 0001193125-24-263398): "On November 21, 2024, Zymeworks Inc. ("Company") issued a press release announcing, with Jazz Pharmaceuticals plc, that the U.S. Food and Drug Administration ("FDA") has granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer ("BTC")." https://www.sec.gov/Archives/edgar/data/1937653/000119312524263398/d769907d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-132299): "Zanidatamab was approved by the U.S. Food and Drug Administration (FDA) in November 2024 for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC 3+) BTC." https://www.sec.gov/Archives/edgar/data/1937653/000119312525132299/d18018dex991.htm
- SEC Form 10-K (accession 0001937653-26-000015): "In November 2024, the Company recognized milestone revenue of $25.0 million from Jazz in relation to the FDA approval of Ziihera (zanidatamab-hrii) for the treatment of HER2+ BTC." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/zyme-20251231.htm
- SEC Form 10-K (accession 0001937653-25-000014): "In November 2024, the Company recognized milestone revenue of $25.0 million from Jazz in relation to the FDA approval of Ziihera® (zanidatamab-hrii) for the treatment of HER2+ BTC." https://www.sec.gov/Archives/edgar/data/1937653/000193765325000014/zyme-20241231.htm

### February 25, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with previously treated, unresectable or metastatic HER2-positive.
- First seen 2025-02-25, last confirmed 2025-02-25.
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000009): "•In 4Q24, announced U.S. FDA granted accelerated approval of Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC)." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000073): "•Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000061): "•Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000025): "•Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 2H25." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/a1q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000009): "◦Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 2H25." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000073): "We remain confident in the opportunity presented by zanidatamab and look forward to sharing the top-line data readout from the Phase 3 HERIZON-GEA-01 trial before the end of the year." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000025): "We also advanced multiple trials across our zanidatamab development program and expect top-line data readout from the HERIZON-GEA-01 trial in 1L GEA in the second half of 2025."" https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/a1q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001651308-25-000029): "•Zanidatamab (HER2 bispecific antibody) in combination with tislelizumab and chemotherapy: anticipate primary PFS data readout from Phase 3 study in first-line HER2-positive gastroesophageal adenocarcinoma in the second half of 2025; and" https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/exhibit991-q42024earningsr.htm

### November 17, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-11-17, last confirmed 2025-11-17.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-283873): "2025) - Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced positive topline results from the Phase 3" https://www.sec.gov/Archives/edgar/data/1937653/000119312525283873/d17392dex991.htm

### December 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-03-02, last confirmed 2026-03-02.
- SEC Form 10-K (accession 0001937653-26-000015): "Under the Jazz Collaboration Agreement, as of December 31, 2025 we have received (i) a non-refundable $50.0 million upfront payment following receipt of HSR Clearance and delivery of licenses and technology transfer to Jazz, (ii) a further payment of $325.0 million following Jazz's decision to continue the collaboration after readout of the top-line clinical data from HERIZON-BTC-01, in addition to our delivery of other data, analyses and other information, and (iii) a milestone payment of $25.0 million in relation to FDA approval of Ziihera (zanidatamab-hrii) for the treatment of HER2+ BTC." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/zyme-20251231.htm

### Q1 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Indication: first-line HER2+ locally advanced or metastatic GEA.
- First seen 2026-02-24, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000012): "- Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA -" https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/a4q25financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000013): "Based on these data, our partner Jazz expects to complete the supplemental Biologics License Application submission for zanidatamab in the first quarter of 2026 for the treatment of first-line HER2+ locally advanced or metastatic GEA under the real-time oncology review program in the U.S., where zanidatamab has been granted Breakthrough Therapy Designation." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/ex991q42025_earningsxrelea.htm

### Apr 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-05-05, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000024): "•In April 2026, FDA accepted the zanidatamab sBLA in GEA for a Priority Review, with a PDUFA date of August 25, 2026." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000033): "In April 2026, the U.S. FDA accepted our partner Jazz's sBLA filing for Ziihera® (zanidatamab-hrii) combinations for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or GEA for priority review with a PDUFA date of August 25, 2026." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/ex991q12026_earningsxrelea.htm

### mid-2026: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-11-17, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-283887): "The trial is ongoing with an additional planned OS interim analysis for Ziihera plus chemotherapy currently expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-010480): "An additional planned OS interim analysis for Ziihera plus chemotherapy is currently expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1937653/000119312526010480/d97670dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-283873): "The trial is ongoing with an additional planned OS interim analysis for Ziihera plus chemotherapy currently expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1937653/000119312525283873/d17392dex991.htm
- SEC Form 10-K (accession 0001937653-26-000015): "An additional planned OS interim analysis for Ziihera plus chemotherapy is currently expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/zyme-20251231.htm

### July 15, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05152147 (A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT05152147

### August 25, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: with first-line.
- First seen 2026-05-05, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000044): "•U.S. Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA)." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000044): "•Prepared to launch zanidatamab in HER2+ 1L GEA (PDUFA date of August 25, 2026)." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000024): "- Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 -" https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000024): "•In April 2026, FDA accepted the zanidatamab sBLA in GEA for a Priority Review, with a PDUFA date of August 25, 2026." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm
- SEC Form 10-Q (accession 0001232524-26-000045): "An sBLA of Ziihera for first-line treatment of HER2-positive locally advanced or metastatic GEA, including cancers of the stomach, gastroesophageal junction and esophagus, in combination with chemotherapy, with or without tislelizumab, was accepted and granted Priority Review by FDA with a PDUFA target action date of August 25, 2026." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm
- SEC Form 10-Q (accession 0001232524-26-000025): "An sBLA of Ziihera for first-line treatment of HER2-positive locally advanced or metastatic GEA, including cancers of the stomach, gastroesophageal junction and esophagus, in combination with chemotherapy, with or without tislelizumab, was accepted and granted Priority Review by FDA with a PDUFA target action date of August 25, 2026." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000025/jazz-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000046): "•August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones" https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earningsxrelea.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000046): "•August 25, 2026 U.S. PDUFA target action date for zanidatamab for the treatment of patients with first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earningsxrelea.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000046): "Operating Expense Discipline: The Company expects significant near-term milestones, including the anticipated closing of the Theravance Biopharma acquisition and the upcoming August 25, 2026 PDUFA date for zanidatamab in GEA, each of which has the potential to immediately expand the Company's revenue and cash flow profile, subject to customary closing conditions and regulatory approval, respectively." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earningsxrelea.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000033): "•Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026" https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/ex991q12026_earningsxrelea.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000033): "In April 2026, the U.S. FDA accepted our partner Jazz's sBLA filing for Ziihera® (zanidatamab-hrii) combinations for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or GEA for priority review with a PDUFA date of August 25, 2026." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/ex991q12026_earningsxrelea.htm
- SEC Form 10-Q (accession 0001937653-26-000047): "In April 2026, the U.S. Food and Drug Administration ("FDA") accepted the sBLA filing for Ziihera® (zanidatamab-hrii) combinations for the first-line treatment of adult patients with HER2+ unresectable locally advanced or metastatic gastric, gastroesophageal junction ("GEJ"), or GEA for priority review with a PDUFA date of August 25, 2026." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000047/zyme-20260630.htm

### August 25, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-08-25, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-058864): "DUBLIN, August 25, 2026 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+)." https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm
- SEC Form 8-K (accession 0001628280-26-058864): "On August 25, 2026, Jazz Pharmaceuticals plc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and chemotherapy (HER2+ IHC 3+ or IHC 2+/ISH+), and Ziihera plus chemotherapy (HER2+ IHC 3+)." https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/jazz-20260825.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000056): "•Ziihera received FDA approval on August 25, 2026, and was launched promptly for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic GEA." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000067): "•On August 25, 2026, our partner Jazz received U.S. FDA approval for two Ziihera-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive GEA." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000067/ex991q32026_earningsxrelea.htm
- SEC Form 8-K (accession 0001937653-26-000051): "As announced on August 25, 2026, Zymeworks' partner, Jazz, has received FDA approval for two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) GEA: Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+)." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000051/zyme-20260825.htm
- SEC Form 10-Q (accession 0001937653-26-000068): "•On August 25, 2026, our partner Jazz Pharmaceuticals received U.S. FDA approval for two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive" https://www.sec.gov/Archives/edgar/data/1937653/000193765326000068/zyme-20260930.htm
- SEC Form 10-Q (accession 0001937653-26-000068): "On August 25, 2026, our partner Jazz received U.S. FDA approval for two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive GEA: Ziihera plus Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+); and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+)." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000068/zyme-20260930.htm

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Breast Cancer; Gastric Cancer; Esophageal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06695845 (A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT06695845

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Breast Cancer; Gastric Cancer; Esophageal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06695845 (A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT06695845

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-08-03, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000044): "•Anticipate the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, based on current pace of event accrual." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000056): "•The company anticipates the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, based on the current pace of event accrual." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: HER2-positive Breast Cancer; Breast Cancer.
- First seen 2026-03-02, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07102381 (A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-29 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT07102381
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000046): "•The EmpowHER-303 trial is expected to complete patient enrollment in mid-2027 with top-line data expected by the end of 2027 or early 2028." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earningsxrelea.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000013): "In January 2026, Jazz updated enrollment guidance for EmpowHER-303 in which they expect to complete enrollment in the first half of 2027, with a top-line data readout later in 2027 or in early 2028." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/ex991q42025_earningsxrelea.htm
- SEC Form 10-Q (accession 0001937653-26-000047): "The EmpowHER-303 trial is expected to complete patient enrollment in mid-2027 with top-line data expected by the end of 2027 or early 2028." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000047/zyme-20260630.htm
- SEC Form 10-K (accession 0001937653-26-000015): "In January 2026, Jazz updated enrollment guidance for EmpowHER-303 in which they expect to complete enrollment in the first half of 2027, with a top-line data readout later in 2027 or in early 2028." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/zyme-20251231.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: HER2-positive Breast Cancer; Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07102381 (A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-29 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT07102381

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metastatic HER2-positive Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06435429 (A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-28 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT06435429

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metastatic HER2-positive Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06435429 (A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-28 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT06435429

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Biliary Tract Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06282575 (Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT06282575

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Biliary Tract Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06282575 (Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT06282575

## Same indication

- [CTX-009](https://sec-api.dev/pdufa/ctx-009) (CMPX)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig) (AZN)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [December 2027](https://sec-api.dev/fda-calendar/2027-12), [April 2028](https://sec-api.dev/fda-calendar/2028-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zanidatamab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ziihera® (zanidatamab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zanidatamab

```bibtex
@misc{secapidev_pdufa_zanidatamab_20261116,
  title        = {Ziihera® (zanidatamab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zanidatamab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zanidatamab_20261116","title":"Ziihera® (zanidatamab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zanidatamab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
